Xenetic Biosciences, Inc. annual report, FY2017

Xenetic Biosciences, Inc. — 2017 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2017; comparison is with fiscal 2016. The filing was signed March 30, 2018. Xenetic is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead candidate, XBIO-101, is in Phase 2 development for progestin-resistant endometrial cancer.

Financial performance and position

Metric	2017	2016
Revenue	$7.585 million	$3.000 million
Operating loss	$3.569 million	$47.431 million
Net loss	$3.595 million	$54.206 million
Loss per share, basic and diluted	$0.41	$7.84
Research and development expense	$4.060 million	$43.738 million
Cash flow from operating activities	$1.494 million provided	$8.787 million used

• 2017 revenue included a $7.5 million one-time sublicense payment from Baxalta, received in November, and $85,000 of collaboration-services revenue. The 2016 revenue was a $3.0 million Shire milestone, recognized in 2016 and collected in January 2017. Future single-digit royalties under the Baxalta sublicense depend on performance of the contemplated sublicense and sales of covered products.
• The sharp reduction in R&D expense primarily reflects the absence of the $39.5 million XBIO-101 in-process research and development charge recorded in 2016 when the asset was acquired. Excluding that charge, R&D fell about 4.2%, to $4.1 million from $4.2 million.
• Operating cash flow was positive in 2017 largely because Xenetic collected the $3.0 million Shire receivable; it does not indicate recurring operating cash generation. Cash and cash equivalents were $5.533 million at year-end, versus $4.048 million a year earlier. Restricted cash was $66,510.
• Year-end working capital was approximately $3.9 million, down from $6.5 million. Current assets were $5.885 million and current liabilities $1.944 million. Total liabilities were $4.862 million; the filing reports no hybrid debt outstanding at year-end. Operating lease commitments totaled $148,246.
• Accumulated deficit was $145.9 million. No meaningful product gross margin is reported because the company had no approved products or product sales.

Material changes and notable items

• Shire discontinued SHP656, a PolyXen-enabled Factor VIII candidate, in May 2017 because it did not meet the study’s predefined once-weekly dosing criterion. The company reported no known drug-related serious adverse events or Factor VIII inhibitors in the trial.
• The October 2017 Baxalta sublicense generated $7.5 million in 2017 revenue and cash. Separately, Shire’s $3.0 million clinical milestone was recognized in 2016 and collected in January 2017.
• XBIO-101’s first Phase 2 patient was dosed in October 2017. The planned open-label study is expected to enroll 72 women; the company said it expected preliminary data before the end of 2018.
• Internal development of ErepoXen was terminated, and Xenetic was seeking to out-license it. OncoHist development remained on hold pending sufficient capital.
• General and administrative expense rose 3.7% to $6.938 million. The filing cites personnel and compensation costs and an approximately $0.6 million fourth-quarter severance accrual associated with the former CEO’s departure. Xenetic also settled a supplier lawsuit in December 2017, paying approximately $0.6 million; a July court ruling had ordered payment of approximately $0.7 million including interest and fees.
• There were no significant cash financing flows in 2017. The company reported 8,717,541 common shares outstanding as of March 16, 2018; preferred shares and outstanding warrants may add dilution.

Outlook, risks and contingencies

• Funding and going concern: Management estimated existing resources would fund planned operations, obligations and commitments only through the second quarter of 2018. Xenetic had no committed additional financing, expected continuing losses, and said it needed to raise capital or pursue strategic alternatives. Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern. If funding is unavailable, Xenetic may reduce or stop development, relinquish rights, restructure or cease operations.
• Development: XBIO-101 is the sole active internal development program described as advancing clinically, making the business highly dependent on its trial results, enrollment, regulatory progress and financing. The filing provides no financial guidance or assurance that the stated preliminary-data timing will be met.
• Partner and revenue concentration: Historical milestone and sublicense receipts were heavily concentrated in Shire/Baxalta. The lost SHP656 program and conditional nature of future sublicense royalties create uncertainty around recurring partner revenue. Further out-licensing efforts were ongoing, but the timing and proceeds could not be reliably predicted.
• Other risks: Xenetic depends on outside manufacturers, CROs and collaborators; faces clinical, regulatory, intellectual-property, competition and reimbursement risks; and may need additional capital that could dilute shareholders or require rights concessions. Pharmsynthez and its affiliates held approximately 61.5% of issued common stock at year-end, creating substantial control and related-party considerations.
• Accounting and contingencies: Goodwill of $3.3 million and indefinite-lived OncoHist IPR&D of $9.2 million were not impaired in 2017, but recoverability depends on uncertain development and commercialization assumptions. No material litigation matters were identified as of December 31, 2017 apart from matters described in the filing.

Important facts for investors to verify

• Whether Xenetic secured sufficient financing after the filing date, and whether the stated second-quarter 2018 runway estimate proved accurate.
• Subsequent XBIO-101 enrollment, trial execution, safety and efficacy updates, and the timing and substance of preliminary results.
• Whether the Baxalta sublicense was performed, whether covered-product sales occurred, and whether any royalties became payable.
• Whether additional licensing or collaboration transactions generated cash, and how dependent revenue remained on a small number of partners.
• Current cash, burn rate, working capital, financing terms, share count, preferred-stock conversion or liquidation rights, and potential warrant dilution.
• Whether the reported non-impairment assumptions for goodwill and OncoHist IPR&D remain supportable given the company’s funding constraints and development plans.